Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artiva Biotherapeutics, Inc.

http://www.artivabio.com/

Latest From Artiva Biotherapeutics, Inc.

Korean Pharmas Race To Globalize But Tacks Vary

Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.

South Korea Business Strategies

Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies

Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.

Deals ImmunoOncology

GC LabCell Taps Alliances In Bid For Lead NK Cell Position

After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.

Regenerative Medicine Cancer

Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva

German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register